Coherus BioSciences, Inc. has announced a clinical collaboration with STORM Therapeutics, Ltd. to evaluate the safety and efficacy of a new drug combination in a Phase 1b/2 study. The study will assess STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor. This trial targets several types of cancer, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer. The Phase 2 portion of the study is set to evaluate expansion cohorts involving up to 188 patients in the United States. Under the agreement, Coherus will supply LOQTORZI, while STORM will serve as the trial sponsor. Both companies retain all commercial rights to their respective compounds.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。